跳至主要内容
临床试验/JPRN-UMIN000010526
JPRN-UMIN000010526已完成未知

Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer without epidermal growth factor receptor mutations: A phase 2 trial. - Efficacy and safety of erlotinib in elderly patients with EGFR wild-type NSCLC.

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine0 个研究点目标入组 42 人开始时间: 2013年4月17日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
75years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Exclusion criteria are as follows 1: History of severe allergic reactions to drugs. 2: Pregnancy or lactation. 3: Willing to get pregnant. 4: Interstitial lung disease. 5: Severe infection. 6; Severe and unstable medical comorbidities. 7: Difficulty in ingestion. 8: Uncontrolled brain metastases. 9: EGFR T790M mutation. 10: Judgment to attending physician.

研究者

发起方
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine

相似试验